Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

Active:	Yes
Cancer Type:	Bladder Cancer	NCT ID:	NCT03711032
Trial Phases:	Phase III	Protocol IDs:	3475-676 (primary) NCI-2019-00740 2018-001967-22 MK-3475-676
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Merck Sharp & Dohme LLC
NCI Full Details:	http://clinicaltrials.gov/show/NCT03711032

Summary

Researchers are looking for new ways to treat high-risk non muscle invasive bladder
cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but
has not spread to the bladder muscle or outside of the bladder. High-risk means NMIBC may
have a high chance of getting worse or coming back after treatment.

The goals of this study are to learn: 1. If more people who receive pembrolizumab with
Bacillus Calmette-Guerin (BCG) have no signs of cancer in their body and live longer
without the cancer growing, spreading, or coming back compared to people who receive BCG
alone. 2. About the safety and how well people tolerate BCG alone or in combination with
pembrolizumab.

Treatment Sites in Georgia

Advanced Urology - Alpharetta
11660 Alpharetta Highway
Building 700, Suite 700
Roswell, GA 30076

Emory University Hospital - Atlanta
1364 Clifton Road NE
Atlanta, GA 30322
www.emoryhealthcare.org

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.